2022
Impact of Social Vulnerability on Comorbid Cancer and Cardiovascular Disease Mortality in the United States
Ganatra S, Dani SS, Kumar A, Khan SU, Wadhera R, Neilan TG, Thavendiranathan P, Barac A, Hermann J, Leja M, Deswal A, Fradley M, Liu JE, Sadler D, Asnani A, Baldassarre LA, Gupta D, Yang E, Guha A, Brown SA, Stevens J, Hayek SS, Porter C, Kalra A, Baron SJ, Ky B, Virani SS, Kazi D, Nasir K, Nohria A. Impact of Social Vulnerability on Comorbid Cancer and Cardiovascular Disease Mortality in the United States. JACC CardioOncology 2022, 4: 326-337. PMID: 36213357, PMCID: PMC9537091, DOI: 10.1016/j.jaccao.2022.06.005.Peer-Reviewed Original ResearchAge-adjusted mortality ratesComorbid cancerCardiovascular diseaseCVD mortalityEpidemiologic Research databaseCardiovascular disease mortalityCross-sectional studyYears of agePublic health interventionsCounty-level mortality dataSignificant urban-rural differencesPrevention WideDisease mortalityResearch DatabaseDisease RegistryMortality rateGreater social vulnerabilityHigh mortalityHealth interventionsUrban-rural differencesCancerDisease controlMortalityMortality dataHighest relative increase
2021
Adverse cardiovascular events in patients treated with mogamulizumab
Kwan J, Henry M, Cook K, Higgins A, Cuomo J, Foss F, Baldassarre L. Adverse cardiovascular events in patients treated with mogamulizumab. American Heart Journal Plus Cardiology Research And Practice 2021, 9: 100049. PMID: 38559371, PMCID: PMC10978139, DOI: 10.1016/j.ahjo.2021.100049.Peer-Reviewed Original ResearchAdverse cardiovascular eventsMogamulizumab therapyCardiovascular eventsHeart failureAdverse outcomesNon-cardiovascular eventsWorld Health Organization databaseFatal adverse outcomesT-cell leukemiaACE occurrenceMogamulizumab treatmentNew hypertensionAdverse eventsCardiac deathVentricular arrhythmiasFatal outcomeUnique patientsCardiovascular toxicityMyocardial infarctionImportant treatmentHigh mortalityPatientsMogamulizumabTherapyOrganization database